Table_1_Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.docx

Purpose: A meta-analysis was conducted to investigate the value of the volume parameters based on somatostatin receptor (SSTR)-positron emission tomography (PET) in predicting the prognosis in patients with neuroendocrine tumors (NETs).
Material: PUBMED, EMBASE, Cochrane library, and Web of Knowledge were searched from January 1990 to May 2021 for studies evaluating prognostic value of volume-based parameters of SSTR PET/CT in NETs. The terms used were “volume,” “positron emission tomography,” “neuroendocrine tumors,” and “somatostatin receptor.” Pooled hazard ratio (HR) values were calculated to assess the correlations between volumetric parameters, including total tumor volume (TTV) and total-lesion SSTR expression (TL-SSTR), with progression-free survival (PFS) and overall survival (OS). Heterogeneity and subgroup analysis were performed. Funnel plots, Begg's and Egger's test were used to assess possible underlying publication bias.
Results: Eight eligible studies involving 593 patients were included in the meta-analysis. In TTV, the pooled HRs of its prognostic value of PFS and OS were 2.24 (95% CI: 1.73–2.89; P < 0.00001) and 3.54 (95% CI, 1.77–7.09; P = 0.0004), respectively. In TL-SSTR, the pooled HR of the predictive value was 1.61 (95% CI, 0.48–5.44, P = 0.44) for PFS.
Conclusion: High TTV was associated with a worse prognosis for PFS and OS in with patients NETs. The TTV of SSTR PET is a potential objective prognosis predictor.

研究目的：本荟萃分析旨在探讨基于生长抑素受体（somatostatin receptor, SSTR）正电子发射断层扫描（positron emission tomography, PET）的体积参数在预测神经内分泌肿瘤（neuroendocrine tumors, NETs）患者预后中的应用价值。
研究资料：检索1990年1月至2021年5月期间PubMed、EMBASE、Cochrane图书馆及Web of Knowledge数据库，筛选评估SSTR PET/CT体积参数对神经内分泌肿瘤预后价值的相关研究，检索词包括"volume"、"positron emission tomography"、"neuroendocrine tumors"及"somatostatin receptor"。通过计算合并风险比（pooled hazard ratio, HR），评估包括总肿瘤体积（total tumor volume, TTV）与全病灶SSTR表达量（total-lesion SSTR expression, TL-SSTR）在内的体积参数与无进展生存期（progression-free survival, PFS）、总生存期（overall survival, OS）的相关性；同时开展异质性分析与亚组分析，并采用漏斗图、Begg检验及Egger检验评估潜在的发表偏倚。
研究结果：本荟萃分析共纳入8项符合纳入标准的研究，涉及593例患者。针对总肿瘤体积，其预测无进展生存期与总生存期的合并风险比分别为2.24（95%CI：1.73–2.89；P < 0.00001）与3.54（95%CI：1.77–7.09；P = 0.0004）。针对全病灶SSTR表达量，其预测无进展生存期的合并风险比为1.61（95%CI：0.48–5.44，P = 0.44）。
研究结论：较高的总肿瘤体积与神经内分泌肿瘤患者更差的无进展生存期及总生存期预后显著相关；基于生长抑素受体PET检测的总肿瘤体积是一项具有潜力的客观预后预测指标。